Search - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly

Filter your results

88 Results
hal_structRnsrIdExt_id : 202124080M
Document type : Journal articles
Document type : Conference papers
Document type : Theses
Document type : Habilitation à diriger des recherches
Document type : Preprints, Working Papers, ...

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

Gwenaelle Gravis , Patricia Marino , Daniel Olive , Frederique Penault-Llorca , Jean-Pierre Delord , et al.
BMC Cancer, 2023, 23 (1), pp.393. ⟨10.1186/s12885-023-10881-8⟩
Journal articles hal-04109560v1

Mechanistic modeling of metastatic relapse in early breast cancer to investigate the biological impact of prognostic biomarkers

Célestin Bigarré , François Bertucci , Pascal Finetti , Gaëtan Macgrogan , Xavier Muracciole , et al.
Computer Methods and Programs in Biomedicine, 2023, 231, pp.107401. ⟨10.1016/j.cmpb.2023.107401⟩
Journal articles hal-04008520v1

Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency

Marie-Christine Etienne-Grimaldi , Nicolas Pallet , Valérie Boige , Joseph Ciccolini , Laurent Chouchana , et al.
European Journal of Cancer, 2023, 181, pp.3-17. ⟨10.1016/j.ejca.2022.11.028⟩
Journal articles hal-03934173v1
Image document

Mechanistic modeling of brain metastases in NSCLC provides computational markers for personalized prediction of outcome

Sebastien Benzekry , Pirmin Schlicke , Pascale Tomasini , Eleonore Simon
Preprints, Working Papers, ... hal-03935739v1
Image document

Structuration d’un programme de dépistage des cancers du poumon incluant un phénotypage clinique, radiologique et biologique utile au développement d’outils de prédiction individualisée du risque - PREVALUNG ETOILE

David Boulate , Dominique Barbolosi
Preprints, Working Papers, ... hal-03926628v1

Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol

David Boulate , Marine Fidelle , Caroline Caramella , Justin Issard , Olivier Planche , et al.
BMJ Open, 2022, 12 (12), ⟨10.1136/bmjopen-2022-067191⟩
Journal articles hal-03926501v1

Therapeutic Drug Monitoring of Biotherapies in oncology: hype or hope

Joseph Ciccolini
PAMM-EORTC 47th Winter Meeting, European Organization for Research and Treatment of Cancer, Dec 2022, Florence, Italy
Conference papers hal-03939677v1
Image document

3MO - Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial

Fabrice Barlesi , Laurent Greillier , Florence Monville , C Audigier-Valette , S. Martinez , et al.
2022 ESMO Immuno-Oncology Congress, Dec 2022, Geneva, Switzerland
Conference papers hal-03928784v1

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors

C. Vicier , N. Isambert , C. Cropet , M. Hamimed , L. Osanno , et al.
ESMO Open, 2022, 7 (6), pp.100646. ⟨10.1016/j.esmoop.2022.100646⟩
Journal articles hal-03923625v1

Place des anti-BRAF dans le mCRC BRAF-mut: aspects pharmacologiques

Joseph Ciccolini
Cours St Paul Oncologie Digestive, Dec 2022, Nice, France
Conference papers hal-03941615v1

Stereotactic radiosurgery for post operative brain metastasic surgical cavities: a single institution experience

Marie Cantaloube , Mohamed Boucekine , Anne Balossier , Xavier Muracciole , Mickael Meyer , et al.
Radiation Oncology, 2022, 17 (1), pp.160. ⟨10.1186/s13014-022-02118-y⟩
Journal articles hal-03926251v1
Image document

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

Elise Timon-David , Carla Perez , Anne Rodallec
Pharmaceutics, 2022, 14 (11), pp.2326. ⟨10.3390/pharmaceutics14112326⟩
Journal articles hal-03924533v1
Image document

Machine-Learning Exploration of Exposure-Effect Relationships of Cisplatin in Head and Neck Cancer Patients

Céleste Cauvin , Laurent Bourguignon , Laure Carriat , Pauline Ghipponi , Abel Mence , et al.
Pharmaceutics, 2022, 14 (11), pp.2509. ⟨10.3390/pharmaceutics14112509⟩
Journal articles hal-03923647v1

Model-informed and PK-guided dosing in the era of immunotherapy

Joseph Ciccolini
APSA-ASCEPT Joint Conference 2022, Australasian Pharmaceutical Science Association and Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Nov 2022, Perth, Australia
Conference papers hal-03934244v1

Renal impairment and DPD testing: Watch out for false‐positive results!

Laure Carriat , Sylvie Quaranta , Caroline Solas , Maelle Rony , Joseph Ciccolini
British Journal of Clinical Pharmacology, 2022, 88 (11), pp.4928-4932. ⟨10.1111/bcp.15482⟩
Journal articles hal-03923650v1

Anti CDK4/6: aspects pharmacologiques et PK/PD

Joseph Ciccolini
Pfizer Internal Symposium, Nov 2022, Paris, France
Conference papers hal-03939710v1

Pharmacokinetics of intact lipid nanocapsules using new quantitative FRET technique

Vincent Lebreton , Norraseth Kaeokhamloed , Anastasiia Vasylaki , Grégory Hilairet , Adélie Mellinger , et al.
Journal of Controlled Release, 2022, 351, pp.681 - 691. ⟨10.1016/j.jconrel.2022.09.057⟩
Journal articles hal-03804976v1
Image document

Semi-mechanistic modelling to show the impact of structural modifications on radiolabeled-dendrimers pharmacokinetics

Jessica Ou , Béatrice Louis , Vincent Nail , Laure Balasse , Ahlem Bouhlel , et al.
DMDG/GMP/SPS, Oct 2022, Amsterdam, Netherlands
Conference papers hal-03930671v1

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant

Olivier Demaria , Laurent Gauthier , Marie Vetizou , Audrey Blanchard Alvarez , Constance Vagne , et al.
Cell Reports Medicine, 2022, 3 (10), pp.100783. ⟨10.1016/j.xcrm.2022.100783⟩
Journal articles hal-03925668v1

Pharmacometrics of immune checkpoint Inhibitors

Joseph Ciccolini
EuroBioMed Workshop, EuroBiomed, Oct 2022, Marseille (FR), France
Conference papers hal-03941559v1

Cancer nanomedicine - from the bench to the bedside: rise of ADC in oncology

Joseph Ciccolini
European Cost Action Nano2clinics, Oct 2022, Roma, Italy
Conference papers hal-03941545v1

Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethic

Anne Rodallec , Cristina Vaghi , Joseph Ciccolini , Raphaëlle Fanciullino , Sebastien Benzekry
PLoS ONE, 2022, 17 (9), pp.e0274886. ⟨10.1371/journal.pone.0274886⟩
Journal articles hal-03924541v1

Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis

Nicolas Penel , Sylvie Bonvalot , André-Michel Bimbai , Alexandra Meurgey , François Le Loarer , et al.
Clinical Cancer Research, 2022, 28 (18), pp.4105-4111. ⟨10.1158/1078-0432.CCR-21-4235⟩
Journal articles hal-03925659v1

LC-MS/MS assay of mAbs in plasma: application in oncology

Joseph Ciccolini
Promise Proteomics Symposium, Sep 2022, Prague, Czech Republic
Conference papers hal-03939703v1

Model Informed Precision Dosing of Biotherapies

Joseph Ciccolini
IATDMCT Congress, Sep 2022, Prague, Czech Republic
Conference papers hal-03934057v1

Stratégies anti-BRAF anti-MEK dans le mélanome: aspects pharmacocinétiques et pharmacodynamiques

Joseph Ciccolini
Journées Horizon Mélanome, Pierre Fabre, Sep 2022, Paris, France
Conference papers hal-03941572v1

TDM of oral targeted therapies: is it worth it?

Joseph Ciccolini
ESMO, European Society of Medical Oncology, Sep 2022, Paris, France
Conference papers hal-03939669v1
Image document

Practical identifiability analysis of a mechanistic model for the time to distant metastatic relapse and its application to renal cell carcinoma

Arturo Álvarez-Arenas , Wilfried Souleyreau , Andrea Emanuelli , Lindsay S Cooley , Jean-Christophe Bernhard , et al.
PLoS Computational Biology, 2022, 18, ⟨10.1371/journal.pcbi.1010444⟩
Journal articles hal-03921339v1

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer

Thi Khanh Le , Chaïma Cherif , Kenneth Omabe , Clément Paris , François Lannes , et al.
Molecular Therapy, 2022, 31 (2), pp.471-486. ⟨10.1016/j.ymthe.2022.08.005⟩
Journal articles hal-03770623v1

Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

Fabrice Barlesi , Laure Deyme , Diane-Charlotte Imbs , Elissa Cousin , Mathieu Barbolosi , et al.
Cancer Chemotherapy and Pharmacology, 2022, 90 (2), pp.149-160. ⟨10.1007/s00280-022-04455-x⟩
Journal articles hal-03923667v1